Veradermics' VDPHL01 meets all primary and secondary endpoints in Phase 3 male hair loss trial

• Veradermics announced positive Phase 3 results for oral VDPHL01 in male pattern hair loss, meeting all primary and secondary endpoints.
• Both dosing regimens improved hair growth versus placebo, with benefits apparent at the earliest assessment.
• Treatment was generally well tolerated, with no treatment-related serious adverse events or cardiac adverse events of special interest.
• The findings complement previously reported trial results, supporting potential FDA approval as a non-hormonal oral treatment for male pattern hair loss.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veradermics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610190700BIZWIRE_USPR_____20261019_BW684103) on October 19, 2026, and is solely responsible for the information contained therein.